Trials / Conditions / Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative

Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative

24 registered clinical trials studyying Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative.

Status	Trial	Sponsor	Phase
Terminated	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524	OHSU Knight Cancer Institute	Phase 1
Active Not Recruiting	Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia NCT03862157	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Completed	Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leuk NCT02092324	OHSU Knight Cancer Institute	Phase 2
Withdrawn	Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant NCT01558778	Roswell Park Cancer Institute	N/A
Completed	Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia NCT01484015	Wake Forest University Health Sciences	Phase 1
Completed	MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia NCT01231919	National Cancer Institute (NCI)	Phase 1
Completed	Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Tran NCT01233921	Martin, Paul	N/A
Completed	Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Canc NCT01053494	Wake Forest University Health Sciences	N/A
Completed	Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy NCT00890747	National Cancer Institute (NCI)	Phase 1
Completed	Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With NCT00856388	Roswell Park Cancer Institute	N/A
Terminated	Aflibercept in Treating Patients With Myelodysplastic Syndromes NCT00509249	National Cancer Institute (NCI)	Phase 2
Terminated	Sunitinib in Treating Patients With Idiopathic Myelofibrosis NCT00387426	National Cancer Institute (NCI)	Phase 2
Completed	3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, NCT00381550	National Cancer Institute (NCI)	Phase 2
Completed	Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases NCT00351975	National Cancer Institute (NCI)	Phase 1
Completed	Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or M NCT00357305	National Cancer Institute (NCI)	Phase 1
Completed	Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treati NCT00397813	Fred Hutchinson Cancer Center	Phase 2
Completed	Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofe NCT00118352	Fred Hutchinson Cancer Center	Phase 2
Completed	Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease i NCT00105001	Fred Hutchinson Cancer Center	Phase 2
Completed	Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With NCT00898079	Children's Oncology Group	—
Completed	Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer NCT00060372	National Cancer Institute (NCI)	Phase 1
Terminated	Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia NCT00049582	National Cancer Institute (NCI)	Phase 1
Terminated	Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leuke NCT00039091	National Cancer Institute (NCI)	Phase 1
Completed	Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction NCT00025415	National Cancer Institute (NCI)	Phase 1
Completed	Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferent NCT02210858	National Cancer Institute (NCI)	Phase 1 / Phase 2